Aurobindo Pharma has overtaken Dr Reddy’s Laboratories in the topline in the financial year 2025-26 with a total revenue of ₹33,653 crore registering a 5.6 percent increase driven by spurt in the revenue from Europe.
Dr Reddy’s Laboratories, which maintained its lead over Aurobindo till FY25, fell behind it in FY26 with a total revenue of ₹33,593 crore.
However, Dr Reddy’s still leads in the bottom line. Even with a 24 percent decline, it posted a net profit of ₹4,285 crore in FY26 while Aurobindo pegged its net profit for the year at ₹3,503 crore.
With Sun Pharma being the top Indian drug maker in terms of revenue, Aurobindo has now become the the second largest Indian Pharma company pushing Dr Reddy’s to the third position.
Both the Hyderabad-based companies have lined up a strong pipeline of innovative products including biosimilars.